BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 19392577)

  • 1. Overcoming obstacles to develop effective and safe siRNA therapeutics.
    Li L; Shen Y
    Expert Opin Biol Ther; 2009 May; 9(5):609-19. PubMed ID: 19392577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo application of RNA interference: from functional genomics to therapeutics.
    Lu PY; Xie F; Woodle MC
    Adv Genet; 2005; 54():117-42. PubMed ID: 16096010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of new RNAi therapeutics.
    Liu G; Wong-Staal F; Li QX
    Histol Histopathol; 2007 Feb; 22(2):211-7. PubMed ID: 17149694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of RNAi technology for targeted therapy--a track of siRNA based agents to RNAi therapeutics.
    Zhou Y; Zhang C; Liang W
    J Control Release; 2014 Nov; 193():270-81. PubMed ID: 24816071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional nanostructures for effective delivery of small interfering RNA therapeutics.
    Hong CA; Nam YS
    Theranostics; 2014; 4(12):1211-32. PubMed ID: 25285170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in siRNA delivery in cancer therapy.
    Singh A; Trivedi P; Jain NK
    Artif Cells Nanomed Biotechnol; 2018 Mar; 46(2):274-283. PubMed ID: 28423924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic targeting in the silent era: advances in non-viral siRNA delivery.
    Guo J; Fisher KA; Darcy R; Cryan JF; O'Driscoll C
    Mol Biosyst; 2010 Jul; 6(7):1143-61. PubMed ID: 20431817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in cell-type specific delivery of RNAi-based therapeutics.
    Dykxhoorn DM
    IDrugs; 2010 May; 13(5):325-31. PubMed ID: 20432190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imaging-guided delivery of RNAi for anticancer treatment.
    Wang J; Mi P; Lin G; Wáng YX; Liu G; Chen X
    Adv Drug Deliv Rev; 2016 Sep; 104():44-60. PubMed ID: 26805788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RNAi-based drug discovery and its application to therapeutics.
    Hokaiwado N; Takeshita F; Banas A; Ochiya T
    IDrugs; 2008 Apr; 11(4):274-8. PubMed ID: 18379962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic siRNA: principles, challenges, and strategies.
    Gavrilov K; Saltzman WM
    Yale J Biol Med; 2012 Jun; 85(2):187-200. PubMed ID: 22737048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biology calls the targets: combining RNAi and disease biology.
    van Es HH; Arts GJ
    Drug Discov Today; 2005 Oct; 10(20):1385-91. PubMed ID: 16253877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical advances of siRNA therapeutics.
    Hu B; Weng Y; Xia XH; Liang XJ; Huang Y
    J Gene Med; 2019 Jul; 21(7):e3097. PubMed ID: 31069898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delivery vehicles for small interfering RNA in vivo.
    de Fougerolles AR
    Hum Gene Ther; 2008 Feb; 19(2):125-32. PubMed ID: 18257677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety profile of RNAi nanomedicines.
    Barros SA; Gollob JA
    Adv Drug Deliv Rev; 2012 Dec; 64(15):1730-7. PubMed ID: 22732527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Running interference: prospects and obstacles to using small interfering RNAs as small molecule drugs.
    Dykxhoorn DM; Lieberman J
    Annu Rev Biomed Eng; 2006; 8():377-402. PubMed ID: 16834561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An update on RNA interference-mediated gene silencing in cancer therapy.
    Ren YJ; Zhang Y
    Expert Opin Biol Ther; 2014 Nov; 14(11):1581-92. PubMed ID: 25010067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Advance in the study of targeting delivery system for siRNA mediated by aptamers].
    Wang XL; Wang QQ; Song HF
    Yao Xue Xue Bao; 2012 Jul; 47(7):850-5. PubMed ID: 22993847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic delivery of siRNA by aminated poly(α)glutamate for the treatment of solid tumors.
    Polyak D; Krivitsky A; Scomparin A; Eliyahu S; Kalinski H; Avkin-Nachum S; Satchi-Fainaro R
    J Control Release; 2017 Jul; 257():132-143. PubMed ID: 27356019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncogene dependency and the potential of targeted RNAi-based anti-cancer therapy.
    Yan R; Hallam A; Stockley PG; Boyes J
    Biochem J; 2014 Jul; 461(1):1-13. PubMed ID: 24927119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.